Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients-Reference-Cited by-同舟云学术

Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients

Published:2022-05-09 Issue:9 Volume:7 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Schrezenmeier Eva^ORCID,Rincon-Arevalo Hector^ORCID,Jens Annika,Stefanski Ana-Luisa^ORCID,Hammett Charlotte,Osmanodja Bilgin,Koch Nadine,Zukunft Bianca,Beck Julia,Oellerich Michael,Proß Vanessa,Stahl Carolin,Choi Mira^ORCID,Bachmann Friederike,Liefeldt Lutz,Glander Petra,Schütz Ekkehard,Bornemann-Kolatzki Kirsten,López del Moral Covadonga,Schrezenmeier Hubert^ORCID,Ludwig Carolin,Jahrsdörfer Bernd^ORCID,Eckardt Kai-Uwe^ORCID,Lachmann Nils^ORCID,Kotsch Katja,Dörner Thomas,Halleck Fabian,Sattler Arne^ORCID,Budde Klemens^ORCID

Funder

see manuscript

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/157836/files/pdf

Reference46 articles.

1. Two Doses of SARS-CoV-2 Vaccines Reduce Risk of Death Due to COVID-19 in Solid Organ Transplant Recipients: Preliminary Outcomes From a UK Registry Linkage Analysis

2. Undoubtedly, kidney transplant recipients have a higher mortality due to COVID‐19 disease compared to the general population

3. Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic;Reischig;Am J Transplant,2021